Myelodysplastic Syndrome with Excess Blasts

Myelodysplastic Syndrome with Excess Blasts — Trials · CancerIndex

Clinical trials

Registered studies

76 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 23
Recruiting: 12
Ph III recruiting: 0
Growth YoY: —
Industry share: 17%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (9)

clinicaltrialsPublishedShowing 1–8 of 8 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05933070	A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML(LAUREL)	terminated	Phase 1	2	Inmune Bio, Inc.INDUSTRY	2	Mar 30, 2026	clinicaltrials
NCT04083170	Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers	terminated	Phase 2	1	Fred Hutchinson Cancer CenterOTHER	1	Jan 1, 2025	clinicaltrials